Sunday, December 22

Tag: Biotechnology Services

Startups Are Using AI to Predict Responses to Cancer Drugs
28Dec By adminNo Comments
World

Startups Are Using AI to Predict Responses to Cancer Drugs

Dec. 28, 2023 12:01 pm ET|WSJ ProBiomedical startups are using artificial intelligence to predict the response patients will have to cancer treatments, aiming to increase the success of drugs in clinical trials and tailor therapies to individuals.As data accumulate from clinical trials and fields such as gene and protein research, AI is helping scientists sift through large volumes of information to uncover signatures that correlate with response—or resistance—to treatment. Startups are using it to predict which drugs are likely to work in clinical studies and create tests to help doctors choose treatments.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
27Dec By adminNo Comments
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:33 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
27Dec By adminNo Comments
World

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell’s last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
How to Ride the Biotech Roller Coaster
26Dec By adminNo Comments
Money

How to Ride the Biotech Roller Coaster

With stocks starting to price in interest-rate cuts next year, the biotech sector has emerged as a winner for investors seeking riskier bets with more distant payoffs.But investing in this industry is tricky because biotech is a sector of haves and have-nots. While every industry has its winners and losers, the gap in biotech is bigger due to the binary nature of drug development. Many companies spend years testing one medical approach or platform. In the end, either the idea works or it doesn’t, and that could be the difference between tripling your investment or losing it all. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion
26Dec By adminNo Comments
World

Bristol-Myers Squibb to Buy RayzeBio for $4.1 Billion

Updated Dec. 26, 2023 12:19 pm ETDrug company Bristol-Myers Squibb struck a $4.1 billion deal to buy RayzeBio, in a bet on a re-emerging cancer drug technology. RayzeBio develops radiopharmaceutical drugs, which use targeted forms of radiation that are delivered directly to cancer cells. Earlier products using the technology struggled commercially, but further research led to another wave of promising therapies that can attack tumors while limiting damage to surrounding healthy cells. Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion
26Dec By adminNo Comments
World

AstraZeneca to Buy Gracell Biotechnologies for $1.2 Billion

AstraZeneca has agreed to buy Gracell Biotechnologies for a transaction value of $1.2 billion, as part of the former’s efforts to grow its cell therapies business.The upfront cash portion of the deal is $1.0 billion, a 62.0% premium to Gracell’s last closing price for its American depository shares of $6.19, AstraZeneca said in a statement Tuesday.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Illumina to Divest Itself of Cancer-Test Maker Grail
18Dec By adminNo Comments
World

Illumina to Divest Itself of Cancer-Test Maker Grail

Gene-sequencing company Illumina said Sunday it will divest itself of cancer blood test maker Grail, following Illumina’s loss in its legal battle against U.S. antitrust regulators.Illumina said it will pursue the divestiture through a third-party sale or capital markets transaction, with a goal of completing terms by the middle of next year.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive 
16Dec By adminNo Comments
World

Court Sides With FTC Finding Illumina-Grail Deal Anticompetitive 

A federal appeals court said the U.S. government was right to challenge Illumina’s purchase of cancer-test developer Grail, but still sent the case back to the Federal Trade Commission for reconsideration.A three-judge panel found the deal to be anticompetitive, but said the FTC erred in how it considered Illumina’s proposed fix for its drawbacks. The judges ordered the FTC to reconsider its opinion on the troubled deal, which the European Commission has already ordered Illumina to unwind.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More
It’s Biotech Stocks’ Time to Shine
13Dec By adminNo Comments
Money

It’s Biotech Stocks’ Time to Shine

These are hard times for the biotech sector. Barely a day goes by without layoffs being announced somewhere in Boston or California, and there are still more than 100 biotech stocks worth less than the cash they have in the bank.Yet there are also very clear signs that the worst might be over for the sector. For investors with a long-term horizon, a recent rally leaves plenty of room for further gains.Copyright ©2023 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
Read More